In situ Generation and Utilization of CO: An Efficient Route
towards N-Substituted Saccharin via Carbonylative Cyclization of 2-Iodosulfonamides
作者:Bhalchandra Bhanage、Sujit Chavan、Adithyaraj K.
DOI:10.1055/s-0036-1588422
日期:2017.9
The present protocol demonstrates the synthesis of N-substituted saccharines via carbonylative cyclization of 2-iodosulfonamides using a Pd(OAc) 2 /Xantphos catalyst system and phenylformate as a CO source. A variety of saccharin derivatives is synthesized under milder reaction conditions.
本协议演示了使用 Pd(OAc) 2 /Xantphos 催化剂系统和苯甲酸作为 CO 源通过 2-碘磺酰胺的羰基化环化合成 N 取代的糖精。多种糖精衍生物是在较温和的反应条件下合成的。
作者:Xiaolong Su、Honggui Huang、Wei Hong、Jianchao Cui、Menglin Yu、Yi Li
DOI:10.1039/c7cc08362a
日期:——
An unprecedented in situ SO2-capture cascade triggered by alkylradicals has been documented herein. Mechanistic investigations suggest that, triggered by alkylradicals, SO2 was released in situ and subsequently fixed into polycyclic small molecules. A wide range of alkylsulfonyl substituted polycyclic compounds were easily prepared with high yields and good functional group tolerability.
Functionalization of α‐C(sp
<sup>3</sup>
)−H Bonds in Amides Using Radical Translocating Arylating Groups
作者:Niklas Radhoff、Armido Studer
DOI:10.1002/anie.202013275
日期:2021.2.15
α‐C−H arylation of N‐alkylamides using 2‐iodoarylsulfonyl radical translocating arylating (RTA) groups is reported. The method allows the construction of α‐quaternary carbon centers in amides. Various mono‐ and disubstituted RTA‐groups are applied to the arylation of primary, secondary, and tertiary α‐C(sp3)−H‐bonds. These radical transformations proceed in good to excellent yields and the cascades
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
[EN] COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES<br/>[FR] PRODUIT DE COMBINAISON POUR LE TRAITEMENT DE MALADIES CANCÉREUSES
申请人:MERCK PATENT GMBH
公开号:WO2021249969A1
公开(公告)日:2021-12-16
The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.